Business Context and Reporting Period
This Form 8-K was filed by Tempest Therapeutics, Inc. on September 17, 2026, reporting events occurring on September 14, 2026. The filing details the entry into a material definitive agreement with Heibei Senlang Biotechnology Co., Ltd., a company based in the People's Republic of China.
Key Financial Metrics and Agreement Terms
The filing does not report standard financial performance metrics such as revenue, profit, cash flow, or debt levels. Instead, it outlines the financial obligations associated with the new collaboration agreement:
- Option Exercise Fee: Approximately $447,000 payable to exercise the exclusive option.
- Nomination Fees: Required for each Selected Licensed Product upon exercise.
- Annual Maintenance Fees: Escalating from $10 million to $14 million over the first three years (subject to potential suspension by the Company with corresponding timeline reductions).
- Royalties: 6% on net sales of Licensed Products.
- Sublicense Revenue: A share of revenue from sublicensing rights.
Material Changes and Strategic Developments
The primary material change is the execution of an exclusive collaboration, option, and license agreement. Key terms include:
- Technology: Access to Senlang's in vivo CAR-T technology.
- Scope: Worldwide rights excluding Greater China.
- Option Period: The Company has four months to exercise the option.
- Greater China Rights: Both parties retain a right of first negotiation for rights within Greater China.
- Commitments: The Company must use commercially reasonable efforts to develop and commercialize at least one Licensed Product and meet specified IND-filing or business-development milestones.
Outlook, Risks, and Contingencies
Management commentary is limited to the press release furnished under Item 7.01. The agreement includes specific termination provisions and risks:
- Termination Triggers: Material breach, bankruptcy, or patent challenges initiated by the Company.
- Termination for Convenience: The Company may terminate the agreement with 90 days' notice.
- Operational Risk: The Company may elect to stop paying annual maintenance fees, which would result in reduced development timelines.
Investor Verification Checklist
- Verify the Company's current cash position to determine if it can afford the $447,000 option fee and potential future maintenance fees.
- Review the full text of the agreement (Exhibit 10.1) for specific definitions of "Selected Licensed Product" and "net sales."
- Assess the timeline for the four-month option exercise period and the associated decision-making process.
- Confirm the status of Senlang's in vivo CAR-T technology and its regulatory standing in the PRC.
- Monitor for any future filings regarding the exercise of the option or the decision to terminate for convenience.